Great webinar, a lot to break down, transparent and facts-based,...

Great webinar, a lot to break down, transparent and facts-based, minimal fluff.

4 quarters of funding remaining, with an 8 mill burn rate (I predicted 3 quarters and 12 mill burn rate), but Q4 will see a higher burn rate. Most likely no cap raise until next year March/April, but could see a spp rights issue. So any CR could be on the back of the PARA 002 stage 1 results release.

Based on the 8 mill burn rate, and factoring in other variables, 72 mill should be more than enough to see the program through to completion and can be split into two lots of capital raises, so not as dire as has been mentioned previously.

Throw into the mix the end of the current bear market and by next year PAR may be raising at a much higher SP than previously feared.

No mention of targeting accelerated or provisional approval as yet, but there could be a change in tone at a moments notice. PARA 008 simply to inform current P3 clinical trial secondary endpoints.

I look forward to others summaries on todays webinar.